Ginkgo Bioworks (DNA) Stock Price, News & Analysis

Company Overview

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Key Stats

• Today's Range: $12.09 to $14.05
• 50-Day Range: $7.11 to $14.92
• 52-Week Range: $5.00 to $16.85
• Volume: 1.97 million shs
• Average Volume: 1.72 million shs
• Market Capitalization: $715.24 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.50
• Consensus Rating: Hold

Ginkgo Bioworks Stock Analysis - MarketRank™

Ginkgo Bioworks scored higher than 25% of companies evaluated by MarketBeat, and ranked 819th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

Ginkgo Bioworks has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Ginkgo Bioworks has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Ginkgo Bioworks are expected to grow in the coming year, from ($10.02) to ($5.99) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Ginkgo Bioworks is -2.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Ginkgo Bioworks is -2.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Ginkgo Bioworks has a P/B Ratio of 0.93. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

27.10% of the float of Ginkgo Bioworks has been sold short.

Short Interest Ratio / Days to Cover

Ginkgo Bioworks has a short interest ratio ("days to cover") of 7.5.

Change versus previous month

Short interest in Ginkgo Bioworks has recently decreased by 13.98%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ginkgo Bioworks does not currently pay a dividend.

Dividend Growth

Ginkgo Bioworks does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

27.10% of the float of Ginkgo Bioworks has been sold short.

Short Interest Ratio / Days to Cover

Ginkgo Bioworks has a short interest ratio ("days to cover") of 7.5.

Change versus previous month

Short interest in Ginkgo Bioworks has recently decreased by 13.98%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.65

News Sentiment

Ginkgo Bioworks has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Ginkgo Bioworks this week, compared to 5 articles on an average week.

Search Interest

Only 6 people have searched for DNA on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Ginkgo Bioworks insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,667.00 in company stock.

Percentage Held by Insiders

Only 9.72% of the stock of Ginkgo Bioworks is held by insiders.

Percentage Held by Institutions

78.63% of the stock of Ginkgo Bioworks is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

DNA Stock Analysis - Frequently Asked Questions

How have DNA shares performed this year?

Ginkgo Bioworks' stock was trading at $9.82 at the start of the year. Since then, DNA stock has increased by 24.4% and is now trading at $12.22.

How were Ginkgo Bioworks' earnings last quarter?

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) announced its quarterly earnings data on Thursday, August, 7th. The company reported ($1.10) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.44) by $0.34. The business earned $49.60 million during the quarter, compared to the consensus estimate of $41.60 million. Ginkgo Bioworks had a negative net margin of 136.56% and a negative trailing twelve-month return on equity of 41.63%.
Read the conference call transcript.

Who are Ginkgo Bioworks' major shareholders?

Top institutional shareholders of Ginkgo Bioworks include Forbes J M & Co. LLP (1.84%), Geode Capital Management LLC (1.60%), Prescott Group Capital Management L.L.C. (1.33%) and Exchange Traded Concepts LLC (0.50%). Insiders that own company stock include Reshma P Shetty, Barry Canton, Marijn E Dekkers, Jason R Kelly, Christian O Henry, Mark E Dmytruk, Harry Sloan, Marie E Fallon and Steven P Coen.
View institutional ownership trends.

How do I buy shares of Ginkgo Bioworks?

Shares of DNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Ginkgo Bioworks own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ginkgo Bioworks investors own include Enovix (ENVX), Symbotic (SYM), JPMorgan Nasdaq Equity Premium Income ETF (JEPQ), COMPASS Pathways (CMPS), Rambus (RMBS), Toast (TOST) and Globant (GLOB).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 8/09/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:DNA
• CIK: 1830214
• Web: www.eagleequityptnrs.com
• Phone: 877-442-5362
• Fax: N/A
• Employees: 640
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Ginkgo Bioworks: $8.50
• High Price Target: $10.00
• Low Price Target: $7.00
• Potential Upside/Downside: -30.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($9.16)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$547.03 million
• Net Margins: -136.56%
• Pretax Margin: -199.02%
• Return on Equity: -41.63%
• Return on Assets: -21.67%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.88
• Quick Ratio: 4.88

Sales & Book Value

• Annual Sales: $227.04 million
• Price / Sales: 3.15
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $13.17 per share
• Price / Book: 0.93

Miscellaneous

• Outstanding Shares: 58,530,000
• Free Float: 52,843,000
• Market Cap: $715.24 million
• Optionable: Optionable
• Beta: 1.50